title: Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
abstract: The role of tandem high-dose chemotherapy (HDC) with autologous peripheral hematopoietic progenitor cell rescue (APHPCR) in patients with Ewing Family Tumors (EFT) is controversial. We initiated treatment for eight consecutive patients with high-risk EFT with HDC and APHPCR from 1992 to 2003. There were no treatment related deaths. Four patients remain in complete remission, including three who did not undergo local therapy to bone at either the primary or metastatic sites. Our experience has shown that treatment of EFT patients with tandem HDC with APHPCR may benefit a subgroup of high-risk patients in whom optimal local therapy is not possible.
authors.affiliation: Division of Hematology, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60614-3394, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Burke
authors.forename: David O
authors.initials: DO
authors.lastname: Walterhouse
authors.forename: David A
authors.initials: DA
authors.lastname: Jacobsohn
authors.forename: Reggie E
authors.initials: RE
authors.lastname: Duerst
authors.forename: Morris
authors.initials: M
authors.lastname: Kletzel
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery / Q000628:therapy; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D018242:Neuroectodermal Tumors, Primitive / Q000188:drug therapy / Q000601:surgery; D010384:Pelvic Bones / Q000601:surgery; D036102:Peripheral Blood Stem Cell Transplantation; D012074:Remission Induction; D012306:Risk; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D012540:Scapula / Q000601:surgery; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide